152 related articles for article (PubMed ID: 37699604)
1. Treatment strategy for de novo metastatic nasopharyngeal carcinoma: a literature review.
Liu Q; Li J; Ng WT; Lee AWM
Chin Clin Oncol; 2023 Aug; 12(4):43. PubMed ID: 37699604
[TBL] [Abstract][Full Text] [Related]
2. Optimal management of oligometastatic nasopharyngeal carcinoma.
Liu H; Yang P; Jia Y
Eur Arch Otorhinolaryngol; 2022 Feb; 279(2):567-576. PubMed ID: 34089384
[TBL] [Abstract][Full Text] [Related]
3. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment.
Zou X; You R; Liu H; He YX; Xie GF; Xie ZH; Li JB; Jiang R; Liu LZ; Li L; Zhang MX; Liu YP; Hua YJ; Guo L; Qian CN; Mai HQ; Chen DP; Luo Y; Shen LF; Hong MH; Chen MY
Eur J Cancer; 2017 May; 77():117-126. PubMed ID: 28391025
[TBL] [Abstract][Full Text] [Related]
4. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
[TBL] [Abstract][Full Text] [Related]
6. Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma.
Lu TZ; Zeng FJ; Hu YJ; Fang M; Zhong FY; Chen BJ; Zhang H; Guo QJ; Pan JJ; Gong XC; Huang SH; Liao ZH; Xia Y; Li JG
Cancer Med; 2023 Dec; 12(24):22091-22102. PubMed ID: 38073447
[TBL] [Abstract][Full Text] [Related]
7. An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma.
Chan SK; O'Sullivan B; Huang SH; Chau TC; Lam KO; Chan SY; Tong CC; Vardhanabhuti V; Kwong DL; Ng CY; Leung TW; Luk MY; Lee AW; Choi HC; Lee VH
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454830
[TBL] [Abstract][Full Text] [Related]
8. Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy.
Yang JH; Sun XS; Xiao BB; Liu LT; Guo SS; Liang JD; Jia GD; Tang LQ; Chen QY; Mai HQ
BMC Cancer; 2021 May; 21(1):534. PubMed ID: 33975558
[TBL] [Abstract][Full Text] [Related]
9. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.
Sun XS; Liu SL; Liang YJ; Chen QY; Li XY; Tang LQ; Mai HQ
Cancer Commun (Lond); 2020 Jan; 40(1):32-42. PubMed ID: 32112522
[TBL] [Abstract][Full Text] [Related]
10. Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance.
Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
Cancer Res Treat; 2019 Oct; 51(4):1259-1268. PubMed ID: 30653745
[TBL] [Abstract][Full Text] [Related]
11. Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
Juarez-Vignon Whaley JJ; Afkhami M; Onyshchenko M; Massarelli E; Sampath S; Amini A; Bell D; Villaflor VM
Curr Treat Options Oncol; 2023 Sep; 24(9):1138-1166. PubMed ID: 37318724
[TBL] [Abstract][Full Text] [Related]
12. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
Yeo BSY; Lee RS; Lim NE; Tan E; Jang IJH; Toh HC; Lim CM
Oral Oncol; 2024 May; 152():106786. PubMed ID: 38615584
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era.
Wang S; Chen S; Zhong Q; Liu Y
J Cancer Res Clin Oncol; 2023 May; 149(5):2071-2079. PubMed ID: 35876949
[TBL] [Abstract][Full Text] [Related]
15. Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma.
Liu ZQ; Zhao YN; Wu YS; Zhang BY; Chen EN; Peng QH; Xiao SM; OuYang D; Xie FY; OuYang PY
Oral Oncol; 2023 Dec; 147():106583. PubMed ID: 37837738
[TBL] [Abstract][Full Text] [Related]
16. Image-based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma.
Shen L; Li W; Wang S; Xie G; Zeng Q; Chen C; Shi F; Zhang Y; Wu M; Shu W; Pan C; Xia Y; Wu P
Radiology; 2016 Sep; 280(3):805-14. PubMed ID: 27023116
[TBL] [Abstract][Full Text] [Related]
17. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
[TBL] [Abstract][Full Text] [Related]
19. Atypical metastasis of nasopharyngeal cancer: noncontiguous spread to the ipsilateral ear.
Sandler ML; Sims JR; Xing MH; Khorsand AS; Brandwein-Weber M; Lee NY; Urken ML
Clin Imaging; 2021 Apr; 72():70-74. PubMed ID: 33217673
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
Huang H; Yao Y; Deng X; Huang Z; Chen Y; Wang Z; Hong H; Huang H; Lin T
Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37417358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
